GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

The FTSE 100 closed down 59.98 points at 8159.63 as traders digest Chancellor Rachel Reeves's Budget today. Among the ...

GSK, which had previously expected the business to grow by a low- to mid-single digit percentage, has cut its 2024 vaccine sales forecast for the second time this year. GSK shares fell 3.19 per ...